Sudbury-based FloSonics Medical has raised $5 million in funding led by iGan Partners.Other investors include Genesys Capital, MaRS Investment Accelerator Fund (IAF), Accel-RX, MaRS Catalyst, Angel One, and Northern Ontario Angels.

Mariner Endosurgery Inc., an innovative Canadian medical device company leading commercialization of computer-assisted medical devices for laparoscopic surgeries, announced today that it has received Investigational Testing Approval (ITA) from Health Canada.  Receipt of the ITA enables the company to initiate clinical testing of Mariner’s LaparoGuard computer-assisted surgery platform which is planned to begin February 2018 at Hamilton General Hospital.  Dr. Niv Sne, trauma surgeon proficient in advanced laparoscopic cases with Hamilton Health Sciences and Associate Professor of Surgery at McMaster University is the principal investigator for the initial studies.

International Data Corporation (IDC) Canada released an IDC Innovators report recognizing Canadian personal health record startups with revenue under C$100 million. CAAP Company Self Care Catalysts were 1 of 4  companies selected evaluated on their ability to offer an innovative new technology, a ground-breaking approach to an existing issue, and/or an interesting new business model in a specific market.

Proteocyte Diagnostics, a company that has designed a platform technology to predict your risk of developing cancer, announces the restructuring and expansion of the Board of Directors with the addition of James Appleyard, Laurence Hicks,  Peter G. Schulam and Carlo Sistilli. Proteocyte is also pleased to announce that Robert Lawrie, the Chair of the Canadian Cancer Society, has agreed to join the Board. 

Trillium Therapeutics Inc. announced the following key additions to its leadership team:

• Blythe Thomson, MD, Executive Medical Director
• Jane E. Cole, RN, Senior Director, Clinical Operations
• Brian E. Jahns, PharmD, Senior Vice President, Commercial and Business Development

OBIO Pre-CAAP Company MedStack announced an enterprise platform collaboration with Sinai Health System to better serve hospitals and digital health entrepreneurs who want to introduce their technology into hospital environments.

VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the first patient has been dosed in a Phase 1/2a clinical study of VBI-1901 for the treatment of recurrent glioblastoma multiforme (rGBM).

ImmunoBiochem, a CAAP company solving the problem of tumor heterogeneity won 2nd place at the highly competitive RESI San Francisco Innovation Challenge last week.

CAAP company ImmunoBiochem, which is solving the problem of tumor heterogeneity by targeting unique proteins enriched in the secretomes of cancer cells with Antibody Drug Conjugates (ADCs) won 2nd place at the highly competitive RESI San Francisco Innovation Challenge

The Canadian Innovation Awards celebrate the best and brightest in the Canadian technology community. Now in its seventh year, the awards acknowledge outstanding startups, innovative businesses and influential individuals. Trexo Robotics advanced to the finals in the New Startup category.

HCell Inc. (Hcell), a biotechnology company focusing on Alopecia Areata in the Pediatric Population, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HC017AA for the treatment of pediatric patients with Alopecia Areata, a devastating hair loss disease.

Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, today announced that it has completed a round of financing that was co-funded by Pfizer R&D Innovate and Genesys Capital. In addition, the company has announced a research collaboration with Pfizer Inc.

Pre-CAAP company Steadiwear's Steadiglove was featured as a technology that stood out for Senior Care at the Aging 2.0 Conference this past November in San Francisco. 

Johnson & Johnson Innovation facilitated an exclusive feasibility study between Janssen Research & Development, LLC and WinterLight Labs. The research will evaluate WinterLight’s proprietary technology for analyzing voice samples obtained from Janssen Research & Development’s ongoing clinical trials in Alzheimer’s and neurodegenerative diseases.

In 2017-18, $5.47 million will be distributed to 12 projects through the Health Technologies Fund. 3 CAAP companies are among the Health Innovation project teams which received funding. Congratulations to Komodo OpenLabs, Eve Medical and BrainFx!

Tracery Opthalmics is a health technology company developing a novel ocular imaging acquisition method and large data analytics platform with the ultimate goal of developing superior biomarkers and measures of disease. Dr. Shelley Boyd, President and CSO delivered the pitch and took home the prize.

DEADLINE TO APPLY: January 12, 2018

The Consulate General of Canada is accepting applications for their fourth annual Dose of the Valley program.

The two-day Life Sciences event includes roundtable discussions, industry-led workshops, one-on-one mentorship, an investor/partnering pitch session, and networking.

Springboard’s Health Innovation Hub is a program for women-led life science and digital health companies seeking seed and growth funding and expert connections. The program runs in two tracks: Life Science and Digital Health.

Selected companies will be matched with a team of relevant, targeted advisors and participate in several in-person and virtual workshops and presentation sessions throughout the year that provide exposure to influencers, active investors, and potential strategic partners.